Oral phenylbutazone in the treatment of acute gouty arthritis

Wilson, Gillian; Huffman, E.R.; Smyth, Charley J.

doi:10.1016/0002-9343(56)90056-0

Cited by 14 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both these variables tended to be positively correlated with duration of attack after starting treatment and may therefore have introduced a bias against naproxen. Nevertheless, the preEent study shows that naproxen is equally as effective as phenylbutazone in the treatment of acute gout, the success rate (87 % phenylbutazone, 83 % naproxen) being similar to that previously reported for phenylbutazone (Boardman and Hart, 1965;Wilson et al, 1956).…”

Section: Discussionsupporting

confidence: 82%

Multicentre trial of naproxen and phenylbutazone in acute gout.

Sturge¹,

Scott²,

Hamilton³

et al. 1977

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

SUMMARY Naproxen 750 mg as a single dose followed by 250 mg three times daily has been compared with phenylbutazone 200 mg four times daily for 48 hours followed by 200 mg three times daily for the treatment of acute gout in an open study on 41 patients.The drugs were equally effective with few and relatively mild side effects. Naproxen is a useful alternative agent for the treatment of acute gout.

show abstract

Section: Discussionsupporting

confidence: 82%

Multicentre trial of naproxen and phenylbutazone in acute gout.

Sturge¹,

Scott²,

Hamilton³

et al. 1977

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

show abstract

“…However, in some cases the uricosuric effect is inadequate in the smaller doses, while larger doses may not be well tolerated, and in such circumstances the patient may experience little or no improvement. Phenylbutazone has been shown to have a good uricosuric effect when administered in doses of 0-6 to 1 g. daily (YU and others, 1953;Bishop and Beecher, 1953;Wyngaarden, 1955), and is also very effective in controlling the acute attacks of gouty arthritis (Kuzell, Schaffarzick, Naugler, Koets, Mankle, Brown, and Champlin, 1955;Wilson, Huffman, and Smyth, 1956). However, its salt retaining properties (Yu and others, 1953;Brodie, Lowman, Bums, and five others, 1954a) and reported toxicity (Kuzell, Schaffarzick, Naugler, Gaudin, Mankle, and Brown, 1954;Kuzell and others, 1955;Mauer, 1955) are a distinct disadvantage and have discouraged to a large extent its use for the treatment of chronic gout (Yu and others, 1953).…”

mentioning

confidence: 99%